Structure for peptidase M01.029: M1 aminopeptidase (Plasmodium spp.)

Summary Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

PDB	Organism	Resolution	Comment
3EBH_A	Plasmodium falciparum	1.65 Å	complex with bestatin
The catalytic zinc atom is shown as a light grey CPK sphere. The zinc ligands are shown in ball-and-stick representation: His496 in purple, His500 in purple and Glu519 in blue. The catalytic residues are shown in ball-and-stick representation: Glu497 in blue and Tyr580 in green. The bound inhibitor bestatin is shown in grey ball-and-stick representation.

		Show surface

TERTIARY STRUCTURE DATA
Comment	Resolution	PDB	PDBe	SCOP	CATH	PDBSum	Proteopedia	Reference
Plasmodium falciparum
structure of the m1 alanylaminopeptidase from malaria	2.10 Å	3EBG	3EBG	3EBG	3EBG	3EBG	3EBG	McGowan et al., 2009
complex with bestatin	1.65 Å	3EBH	3EBH	3EBH	3EBH	3EBH	3EBH	McGowan et al., 2009
complex with the phosphinate dipeptide analog	2.00 Å	3EBI	3EBI	3EBI	3EBI	3EBI	3EBI	McGowan et al., 2009
mature peptidase	1.80 Å	3Q43	3Q43	3Q43	3Q43	3Q43	3Q43	Velmourougane et al., 2011
mature peptidase	1.80 Å	3Q44	3Q44	3Q44	3Q44	3Q44	3Q44	Velmourougane et al., 2011
mature peptidase	1.80 Å	3T8V	3T8V	3T8V	3T8V	3T8V	3T8V	Harbut et al., 2011
mature peptidase	2.20 Å	4J3B	4J3B	4J3B	4J3B	4J3B	4J3B	Dalal et al., 2013
mature peptidase	1.91 Å	4K5L	4K5L	4K5L	4K5L	4K5L	4K5L	Kannan et al., 2013
mature peptidase	1.75 Å	4K5M	4K5M	4K5M	4K5M	4K5M	4K5M	Kannan et al., 2013
mature peptidase	1.91 Å	4K5N	4K5N	4K5N	4K5N	4K5N	4K5N	Kannan et al., 2013
mature peptidase	1.90 Å	4K5O	4K5O	4K5O	4K5O	4K5O	4K5O	Kannan et al., 2013
mature peptidase	1.85 Å	4K5P	4K5P	4K5P	4K5P	4K5P	4K5P	Kannan et al., 2013
mature peptidase	1.98 Å	4R5T	4R5T	4R5T	4R5T	4R5T	4R5T	Mistry et al., 2014
mature peptidase	2.10 Å	4R5V	4R5V	4R5V	4R5V	4R5V	4R5V	Mistry et al., 2014
mature peptidase	1.85 Å	4R5X	4R5X	4R5X	4R5X	4R5X	4R5X	Mistry et al., 2014
mature peptidase	1.60 Å	4X2U	4X2U	4X2U	4X2U	4X2U	4X2U	Drinkwater et al., 2015
crystal structure of pfa-m1 with virtual ligand inhibitor	1.98 Å	4ZQT	4ZQT	4ZQT	4ZQT	4ZQT	4ZQT
complex with hydroxamic acid- based inhibitor 9b	1.80 Å	4ZW3	4ZW3	4ZW3	4ZW3	4ZW3	4ZW3
complex with hydroxamic acid- based inhibitor 9f	1.80 Å	4ZW5	4ZW5	4ZW5	4ZW5	4ZW5	4ZW5
complex with hydroxamic acid- based inhibitor 9q	1.90 Å	4ZW6	4ZW6	4ZW6	4ZW6	4ZW6	4ZW6
complex with hydroxamic acid- based inhibitor 9m	1.95 Å	4ZW7	4ZW7	4ZW7	4ZW7	4ZW7	4ZW7
complex with hydroxamic acid- based inhibitor 9r	2.00 Å	4ZW8	4ZW8	4ZW8	4ZW8	4ZW8	4ZW8
complex with hydroxamic acid- based inhibitor 10b	2.00 Å	4ZX3	4ZX3	4ZX3	4ZX3	4ZX3	4ZX3
complex with hydroxamic acid- based inhibitor 10o	1.90 Å	4ZX4	4ZX4	4ZX4	4ZX4	4ZX4	4ZX4
complex with hydroxamic acid- based inhibitor 10q	1.95 Å	4ZX5	4ZX5	4ZX5	4ZX5	4ZX5	4ZX5
complex with hydroxamic acid- based inhibitor 10s	2.05 Å	4ZX6	4ZX6	4ZX6	4ZX6	4ZX6	4ZX6
complex with (s)-2-((2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido)-n-hydroxy- 4-methylpentanamide	1.96 Å	5XM7	5XM7	5XM7	5XM7	5XM7	5XM7
complex with (s)-2-((2s,3r)-3-amino-2-hydroxy-4-phenylbutanamido)- n-hydroxy-4-methylpentanamide. ***caveat 5y19 thr a 492 has wrong chirality at atom cb	1.83 Å	5Y19	5Y19	5Y19	5Y19	5Y19	5Y19
complex with (s)-2-(3-(2,4-difluorobenzyl)ureido)-n-hydroxy-4- methylpentanamide	1.73 Å	5Y1H	5Y1H	5Y1H	5Y1H	5Y1H	5Y1H
complex with (s)-2-(3-(2-chlorobenzyl)ureido)-n-hydroxy-4-methylpentanamide	1.81 Å	5Y1K	5Y1K	5Y1K	5Y1K	5Y1K	5Y1K
complex with (s)-2-(3-(3-chlorobenzyl)ureido)-n-hydroxy-4-methylpentanamide	2.14 Å	5Y1Q	5Y1Q	5Y1Q	5Y1Q	5Y1Q	5Y1Q
complex with (s)-n-hydroxy-4-methyl-2-(3-( o-tolyl)ureido)pentanamide	1.69 Å	5Y1R	5Y1R	5Y1R	5Y1R	5Y1R	5Y1R
complex with (s)-2-(3-(3,4-dimethylbenzyl)ureido)-n-hydroxy-4- methylpentanamide	1.66 Å	5Y1S	5Y1S	5Y1S	5Y1S	5Y1S	5Y1S
complex with (s)-2-(3-(2,3-dimethylbenzyl)ureido)-n-hydroxy-4- methylpentanamide	2.14 Å	5Y1T	5Y1T	5Y1T	5Y1T	5Y1T	5Y1T
complex with (s)-2-(3-(2,6-diethylphenyl)ureido)- n-hydroxy-4- methylpentanamide	1.62 Å	5Y1V	5Y1V	5Y1V	5Y1V	5Y1V	5Y1V
crystal structure of plasmodium falciparum aminopeptidase n with magnesium bound to active site zinc	1.56 Å	5Y1W	5Y1W	5Y1W	5Y1W	5Y1W	5Y1W
complex with actinonin	1.55 Å	5Y1X	5Y1X	5Y1X	5Y1X	5Y1X	5Y1X
complex with (s)-n-hydroxy-4-methyl-2-(3-(3-methylbenzyl)ureido)pentanamide	1.73 Å	5Y3I	5Y3I	5Y3I	5Y3I	5Y3I	5Y3I
complex with inhibitor (6da) and catalytic zinc ion	1.82 Å	6EA1	6EA1	6EA1	6EA1	6EA1	6EA1
complex with inhibitor (6h) and catalytic zinc ion	1.35 Å	6EA2	6EA2	6EA2	6EA2	6EA2	6EA2
complex with inhibitor (6i) and catalytic zinc ion	1.65 Å	6EAA	6EAA	6EAA	6EAA	6EAA	6EAA
complex with inhibitor (6j) and catalytic zinc ion	1.85 Å	6EAB	6EAB	6EAB	6EAB	6EAB	6EAB
complex with inhibitor (6k) and catalytic zinc ion	1.82 Å	6EE3	6EE3	6EE3	6EE3	6EE3	6EE3
complex with inhibitor (6m) and catalytic zinc ion	1.58 Å	6EE4	6EE4	6EE4	6EE4	6EE4	6EE4
complex with inhibitor (6o) and catalytic zinc ion	1.50 Å	6EE6	6EE6	6EE6	6EE6	6EE6	6EE6
complex with inhibitor (6p) and catalytic zinc ion	1.50 Å	6EED	6EED	6EED	6EED	6EED	6EED